title: GPR30: a novel indicator of poor survival for endometrial carcinoma.
abstract: OBJECTIVE
  This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma.
  
  
  METHODS
  Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival.
  
  
  RESULTS
  GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005).
  
  
  CONCLUSIONS
  GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.
authors.affiliation: Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Hsmith@salud.unm.edu
authors.forename: Harriet O
authors.initials: HO
authors.lastname: Smith
authors.forename: Kimberly K
authors.initials: KK
authors.lastname: Leslie
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Singh
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Qualls
authors.forename: Chetana M
authors.initials: CM
authors.lastname: Revankar
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Joste
authors.forename: Eric R
authors.initials: ER
authors.lastname: Prossnitz
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D015331:Cohort Studies; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D043562:Receptors, G-Protein-Coupled / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C109584:GPER1 protein, human; D011960:Receptors, Estrogen; D043562:Receptors, G-Protein-Coupled